Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Sold by Cornercap Investment Counsel Inc.

Cornercap Investment Counsel Inc. lessened its stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 53.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,583 shares of the company’s stock after selling 25,527 shares during the quarter. Cornercap Investment Counsel Inc.’s holdings in Black Diamond Therapeutics were worth $98,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Acadian Asset Management LLC grew its stake in shares of Black Diamond Therapeutics by 13.8% in the 1st quarter. Acadian Asset Management LLC now owns 170,510 shares of the company’s stock valued at $864,000 after buying an additional 20,616 shares during the period. SG Americas Securities LLC purchased a new position in Black Diamond Therapeutics in the second quarter worth approximately $108,000. Bank of New York Mellon Corp acquired a new stake in Black Diamond Therapeutics during the second quarter worth $508,000. Rhumbline Advisers increased its stake in Black Diamond Therapeutics by 10,334.3% during the second quarter. Rhumbline Advisers now owns 46,850 shares of the company’s stock worth $218,000 after acquiring an additional 46,401 shares during the last quarter. Finally, Foundations Investment Advisors LLC raised its position in Black Diamond Therapeutics by 17.7% in the second quarter. Foundations Investment Advisors LLC now owns 113,550 shares of the company’s stock valued at $529,000 after purchasing an additional 17,050 shares during the period. Hedge funds and other institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Stock Down 4.6 %

NASDAQ:BDTX opened at $2.50 on Tuesday. The firm’s fifty day simple moving average is $3.83 and its 200-day simple moving average is $4.91. The stock has a market cap of $141.46 million, a PE ratio of -1.88 and a beta of 2.51. Black Diamond Therapeutics, Inc. has a fifty-two week low of $2.12 and a fifty-two week high of $7.66.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.09. Equities analysts anticipate that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

BDTX has been the subject of several recent research reports. Wedbush reissued an “outperform” rating and issued a $16.00 price objective on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th. Raymond James started coverage on shares of Black Diamond Therapeutics in a research report on Wednesday, July 31st. They issued an “outperform” rating and a $20.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Black Diamond Therapeutics in a research note on Wednesday, November 6th. Finally, Piper Sandler boosted their target price on Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, September 23rd.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.